Award
NIH Reporter #5R42TR004338-03
Novel strategy to block AAV neutralizing antibody activity
Recipient
NABGEN, INC.
Award Amount
$1,014,676.00
Ceiling
$1,014,676.00
Awarded
August 25, 2026
Identifier
5R42TR004338-03
Award for developing a protein M mutant to block AAV neutralizing antibodies, enhancing gene therapy and therapeutic delivery, funded by NCATS.
Description
The project involves developing a stable and effective protein M mutant (NG101) to block AAV neutralizing antibodies, with applications in gene therapy and broader therapeutic delivery. The project aims to extend the technology for use in cancer treatment and vaccination.